Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STATEsMAN phase 2 sacituzumab tirumotecan in metastatic castration-resistant prostate cancer
ACTRN12625001382460Phase 2Not yet recruiting
- Sponsor
- Metro South Health
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa), sponsored by Metro South Health. Primary endpoint: PSA50 response rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12625001382460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001382460.